| Ticker Details |
Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.
|
| IPO Date: |
February 19, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.76B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 2.97%
|
| Avg Daily Range (30 D): |
$0.04 | 0.22%
|
| Avg Daily Range (90 D): |
$0.09 | 0.81%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.97M |
| Avg Daily Volume (30 D): |
1.57M |
| Avg Daily Volume (90 D): |
2.05M |
| Trade Size |
| Avg Trade Size (Sh.): |
128 |
| Avg Trade Size (Sh.) (30 D): |
229 |
| Avg Trade Size (Sh.) (90 D): |
146 |
| Institutional Trades |
| Total Institutional Trades: |
4,880 |
| Avg Institutional Trade: |
$2.4M |
| Avg Institutional Trade (30 D): |
$2.5M |
| Avg Institutional Trade (90 D): |
$2.64M |
| Avg Institutional Trade Volume: |
.19M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3M |
| Avg Closing Trade (30 D): |
$6.75M |
| Avg Closing Trade (90 D): |
$4.17M |
| Avg Closing Volume: |
252.45K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.32
|
$.23
|
$.16
|
|
Diluted EPS
|
$-.37
|
$.21
|
$.14
|
|
Revenue
|
$330.51M
|
$94.88M
|
$95.44M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-43.4M
|
$26.93M
|
$18.72M
|
|
Operating Income / Loss
|
$10.44M
|
$21.27M
|
$14.43M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$40.94M
|
$61.15M
|
$47.41M
|
|
PE Ratio
|
|
|
|
|
|
|
